---
title: "ENGENE HOLDINGS INC C/WTS 31/10/2028 (TO PUR COM) CL A | 8-K: FY2025 Q2 EPS: USD -0.51"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244252183.md"
datetime: "2025-06-12T12:08:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244252183.md)
  - [en](https://longbridge.com/en/news/244252183.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244252183.md)
generator: "portal-rs"
---

# ENGENE HOLDINGS INC C/WTS 31/10/2028 (TO PUR COM) CL A | 8-K: FY2025 Q2 EPS: USD -0.51

EPS: As of FY2025 Q2, the actual value is USD -0.51.

### Cash and Marketable Securities

-   As of April 30, 2025, enGene Holdings Inc. reported cash, cash equivalents, and marketable securities totaling $251.5 million, which is expected to fund operations into 2027.

### Operating Expenses

-   Total operating expenses for the three months ended April 30, 2025, were $27.1 million, compared to $17.3 million for the same period in 2024. This increase was primarily due to a $10.4 million rise in research and development expenses, driven by higher manufacturing and clinical costs related to the LEGEND study and personnel-related costs.

### Net Loss

-   The net loss attributable to common shareholders for the three months ended April 30, 2025, was approximately $25.8 million, or $0.51 per share, compared to approximately $15.0 million, or $0.38 per share, for the same period in 2024. The increase in net loss is mainly attributed to the rise in operating expenses, partially offset by net interest income.

### Total Assets and Liabilities

-   Total assets as of April 30, 2025, were $266.7 million, with total liabilities of $39.4 million, resulting in total shareholders’ equity of $227.3 million.

### Outlook / Guidance

-   enGene plans to file a Biologics License Application (BLA) for detalimogene in mid-2026, with ongoing updates from the LEGEND study expected in the second half of 2025. The company has completed EMA Scientific Advice, indicating potential suitability for a Conditional Marketing Authorization Application, assuming a positive benefit-risk ratio.

### Related Stocks

- [ENGNW.US](https://longbridge.com/en/quote/ENGNW.US.md)

## Related News & Research

- [OpenAI, Anthropic bankers seek investment-grade credit ratings post-IPO, FT says](https://longbridge.com/en/news/298259727.md)
- [TECHNICALS-US oil may retest resistance at $92.89](https://longbridge.com/en/news/298251483.md)
- [Oil rises as risks of prolonged Mideast conflict heighten supply worries](https://longbridge.com/en/news/298241307.md)
- [Where Will Paramount Skydance (NASDAQ:PSKY) Move To?](https://longbridge.com/en/news/298231998.md)
- [Is TTM Technologies (TTMI) Fully Valued Following Its AI Driven Earnings Beat?](https://longbridge.com/en/news/298240590.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**